<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; hamied</title>
	<atom:link href="http://www.tapanray.in/tag/hamied/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>India’s China Dependence On API: A Time To Think ‘Outside The Box’</title>
		<link>http://www.tapanray.in/indias-china-dependence-on-api-a-time-to-think-outside-the-box/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-china-dependence-on-api-a-time-to-think-outside-the-box</link>
		<comments>http://www.tapanray.in/indias-china-dependence-on-api-a-time-to-think-outside-the-box/#comments</comments>
		<pubDate>Mon, 21 Sep 2015 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[Active]]></category>
		<category><![CDATA[Advisor]]></category>
		<category><![CDATA[Ananth Kumar]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[ASSOCHAM]]></category>
		<category><![CDATA[bulk]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[dependence]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[ingredients]]></category>
		<category><![CDATA[Katoch]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[out of box]]></category>
		<category><![CDATA[outside]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recommendations]]></category>
		<category><![CDATA[secretary]]></category>
		<category><![CDATA[Security]]></category>
		<category><![CDATA[Subburaj]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[year of API]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7086</guid>
		<description><![CDATA[The Department of Pharmaceuticals (DoP) has declared the Year 2015 as the Year of ‘Active Pharmaceutical Ingredient (API)’. Following it up on February 25, 2015, the Union Minister of Chemicals &#38; Fertilizers Ananth Kumar assured the Pharmaceutical Industry that appropriate &#8230; <a href="http://www.tapanray.in/indias-china-dependence-on-api-a-time-to-think-outside-the-box/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-china-dependence-on-api-a-time-to-think-outside-the-box/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Gilead: Caught Between A Rock And A Hard Place In India</title>
		<link>http://www.tapanray.in/gilead-caught-between-a-rock-and-a-hard-place-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=gilead-caught-between-a-rock-and-a-hard-place-in-india</link>
		<comments>http://www.tapanray.in/gilead-caught-between-a-rock-and-a-hard-place-in-india/#comments</comments>
		<pubDate>Mon, 22 Sep 2014 00:00:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Alliance]]></category>
		<category><![CDATA[Between. Rock]]></category>
		<category><![CDATA[Cadila Healthcare]]></category>
		<category><![CDATA[Caught]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[hard]]></category>
		<category><![CDATA[Hepatitis C]]></category>
		<category><![CDATA[Hetero labs and Sequent Scientific]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPA]]></category>
		<category><![CDATA[IPO. Indian]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[monopolies]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Place]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Strides Arcolab]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tenofovir]]></category>
		<category><![CDATA[Voluntary]]></category>
		<category><![CDATA[yusuf]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6001</guid>
		<description><![CDATA[I had mentioned in my blog post of August 4, 2014, titled “Hepatitis C: A Silent, Deadly Disease: Treatment beyond reach of Most Indians” that in line with Gilead’s past approach to its HIV medicines, the company would offer to &#8230; <a href="http://www.tapanray.in/gilead-caught-between-a-rock-and-a-hard-place-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/gilead-caught-between-a-rock-and-a-hard-place-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does Patent Expiry Matter Less For Difficult To Copy Drugs?</title>
		<link>http://www.tapanray.in/does-patent-expiry-matter-less-for-difficult-to-copy-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-patent-expiry-matter-less-for-difficult-to-copy-drugs</link>
		<comments>http://www.tapanray.in/does-patent-expiry-matter-less-for-difficult-to-copy-drugs/#comments</comments>
		<pubDate>Mon, 08 Sep 2014 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advair]]></category>
		<category><![CDATA[aerosol]]></category>
		<category><![CDATA[AirFluSal Forspiro]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[COPD]]></category>
		<category><![CDATA[copy]]></category>
		<category><![CDATA[difficult]]></category>
		<category><![CDATA[Diskus]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inhaler]]></category>
		<category><![CDATA[less]]></category>
		<category><![CDATA[matters]]></category>
		<category><![CDATA[NDDS]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[ParaIV]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[Seretide]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[witty]]></category>
		<category><![CDATA[yusuf]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5865</guid>
		<description><![CDATA[“Patent expiry matters much less for difficult to copy drugs”. Not so long ago, this is what many used to believe in the pharma industry. However, looking at the current trend involving the tech savvy generic players, it appears, gone &#8230; <a href="http://www.tapanray.in/does-patent-expiry-matter-less-for-difficult-to-copy-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-patent-expiry-matter-less-for-difficult-to-copy-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Fire in The Blood”: A Ghastly Patents Vs Patients War &#8211; for Pricing Freedom?</title>
		<link>http://www.tapanray.in/fire-in-the-blood-a-ghastly-patents-vs-patients-war-for-pricing-freedom/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=fire-in-the-blood-a-ghastly-patents-vs-patients-war-for-pricing-freedom</link>
		<comments>http://www.tapanray.in/fire-in-the-blood-a-ghastly-patents-vs-patients-war-for-pricing-freedom/#comments</comments>
		<pubDate>Mon, 07 Oct 2013 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[blood]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[CSR]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Dylan]]></category>
		<category><![CDATA[fire]]></category>
		<category><![CDATA[ghastly]]></category>
		<category><![CDATA[Gray]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Innovators]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Mohan]]></category>
		<category><![CDATA[obscene]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[story]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[war]]></category>
		<category><![CDATA[yusuf]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3776</guid>
		<description><![CDATA[International award winning documentary film, &#8216;FIRE IN THE BLOOD&#8217; could possibly set a raging fire in your blood too, just like mine. It made me SAD, REFLECTIVE and ANGRY, prompting to share &#8216;MY TAKE AWAYS&#8217; with you on this contentious subject, immediately after I put &#8230; <a href="http://www.tapanray.in/fire-in-the-blood-a-ghastly-patents-vs-patients-war-for-pricing-freedom/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/fire-in-the-blood-a-ghastly-patents-vs-patients-war-for-pricing-freedom/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An El Dorado&#8230;But Not Without Responsible Pricing:The Cancer Segment in India</title>
		<link>http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area</link>
		<comments>http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/#comments</comments>
		<pubDate>Mon, 04 Feb 2013 00:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[area]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[breast]]></category>
		<category><![CDATA[British]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cervical]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Eldorado]]></category>
		<category><![CDATA[female]]></category>
		<category><![CDATA[gold]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[lung]]></category>
		<category><![CDATA[male]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPP2012]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[oral]]></category>
		<category><![CDATA[ovarian]]></category>
		<category><![CDATA[ovary]]></category>
		<category><![CDATA[pancreatic]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[pot]]></category>
		<category><![CDATA[pots]]></category>
		<category><![CDATA[PPP]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[responsible]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[segment]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[urban]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[yusuf]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=1493</guid>
		<description><![CDATA[The affordability issue for cancer treatment has been the subject of a raging debate since quite some time, as the incidence of cancer is fast increasing across the world. Just for example a very recent report highlighted that cancer has now become the &#8230; <a href="http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
